SELECT PUBLICATIONS

Escudier B et al. A randomized, controlled, double-blind phase III study (AVOREN)
of bevacizumab/interferon-2a vs placebo/interferon-α2a as first-line therapy in
metastatic renal cell carcinoma. Proc ASCO 2007;Abstract 3.

Hutson TE et al. Pazopanib (GW786034) is active in metastatic renal cell carcinoma (RCC): Interim results of a phase II randomized discontinuation trial (RDT). Proc ASCO 2007;Abstract 5031.

Klatte T et al. Understanding the natural biology of kidney cancer: Implications for
targeted cancer therapy. Rev Urol 2007;9(2):47-56. Abstract

Ratain MJ et al. Phase II placebo-controlled randomized discontinuation trial of
sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24(16):2505-
12. Abstract

Stadler WM et al. Successful implementation of the randomized discontinuation trial
design: An application to the study of the putative antiangiogenic agent carboxyaminoimidazole
in renal cell carcinoma — CALGB 69901. J Clin Oncol 2005;23(16):3726-32.Abstract.

Vogelzang N. Targeted therapies for renal cell carcinoma: A new standard of care.
Available at: www.medscape.com/viewarticle/541604.

 

 

 

 

 

 

 

 

 

 

Home

Editor
Neil Love, MD

Interviews

David I Quinn, MBBS, PhD
- Select publications

Walter Stadler, MD
- Select publications

Mario Lacouture, MD
- Select publications

Bernard J Escudier, MD
- Select publications

CME Information

Faculty Disclosures

Editor's Office